Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development
Crossref DOI link: https://doi.org/10.1038/onc.2016.315
Published Online: 2016-09-05
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tsai, C T
So, C W E
Text and Data Mining valid from 2016-09-05
Article History
Received: 25 May 2016
Revised: 5 July 2016
Accepted: 17 July 2016
First Online: 5 September 2016
Competing interests
: The authors declare no conflict of interest.